12/22/2014 - 3:09 PM EST - Tekmira Pharmaceuticals Corporation : has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year, subject to finalization of a suitable clinical protocol. Tekmira Pharmaceuticals Corporation
shares T.TKM are trading up $0.28 at $15.53.
